Wegovy vs. Zepbound: Which Weight Loss Injection Wins in 2026?

Two years ago, getting a GLP-1 prescription meant navigating a shortage, a steep copay, and a long waiting list. In 2026, the landscape has shifted dramatically — Wegovy and Zepbound are both widely available, compounded alternatives exist at accessible price points, and millions of people are choosing between the two every month. So which one is actually better?

The honest answer: it depends on your body, your goals, and your tolerance profile. But there's a clear winner in the clinical data for average weight loss — and there are real reasons why some people should still choose the runner-up. Here's everything you need to make the right call.

Semaglutide vs. Tirzepatide: What's Actually Different?

Wegovy contains semaglutidea GLP-1 receptor agonist. It mimics the hormone glucagon-like peptide-1, which your gut releases after you eat. GLP-1 signals the brain to feel full, slows gastric emptying, and reduces glucagon release — all of which mean you naturally eat less and burn glucose more efficiently.

Zepbound contains tirzepatidewhich does everything semaglutide does — but also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone that plays a role in fat storage and insulin sensitivity. By hitting both receptors simultaneously, tirzepatide essentially pulls two levers where semaglutide pulls one.

This dual-agonism is why most head-to-head comparisons — and the clinical trials — show tirzepatide producing greater average weight loss. But mechanism alone doesn't tell the whole story.

What the Clinical Trials Actually Show

The STEP Trials (Semaglutide / Wegovy)

The landmark STEP 1 trial enrolled 1,961 adults with obesity and found that semaglutide 2.4 mg weekly produced an average weight loss of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo. About 86% of participants lost at least 5% of their body weight, and roughly one-third lost more than 20%.

STEP 2 (people with type 2 diabetes), STEP 3 (with intensive behavioral therapy), and STEP 4 (maintenance after dose escalation) confirmed the drug's efficacy across populations and showed that weight rebounded significantly when medication was stopped — about two-thirds of the weight returned within a year.

The SURMOUNT Trials (Tirzepatide / Zepbound)

The SURMOUNT-1 trial enrolled 2,539 adults without diabetes and tested three doses of tirzepatide (5, 10, and 15 mg). At the highest dose, participants lost an average of 20.9% of body weight at 72 weeks — nearly 6 percentage points more than semaglutide in STEP 1. Over 56% of participants at the 15 mg dose lost at least 20% of their body weight.

SURMOUNT-2 (with type 2 diabetes) and SURMOUNT-3 (after intensive lifestyle intervention) reinforced the pattern: tirzepatide consistently outperforms semaglutide on average percentage weight lost.

Direct Comparison: SURPASS-CVOT and Real-World Data

While no head-to-head RCT has directly compared Wegovy to Zepbound in the same trial, real-world retrospective data published in 2025 in JAMA Internal Medicine found tirzepatide users lost significantly more weight over 12 months than matched semaglutide users. The advantage held across BMI categories and age groups.

Side Effects: How Do They Compare?

Both medications share a very similar side effect profile because both work on GLP-1 receptors. The most common issues are:

• Nausea — very common at the start of each new dose level; usually fades within 1–2 weeks
• Vomiting — less common than nausea; often avoidable by eating slowly and in small portions
• Constipation — gastric emptying slows, so bowel movements slow too; fiber and hydration help
• Diarrhea — some people experience this instead of constipation, especially early on
• Fatigue — often temporary, especially during the titration phase
• GERD/heartburn — can worsen with delayed gastric emptying

Tirzepatide appears to cause slightly more GI symptoms in some users during titration — likely because it's hitting GIP receptors in addition to GLP-1. However, individual variation is enormous. Some people breeze through tirzepatide and struggle with semaglutide, and vice versa. The best approach is to start low, go slow, and give your body 2–4 weeks to adjust at each dose level.

One important consideration: both drugs carry a boxed warning about thyroid C-cell tumors based on rodent studies. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use either medication.

Cost Comparison in 2026

For most people without strong insurance coverage, compounded GLP-1s represent the most accessible path. Read our full breakdown of compounded vs. brand-name GLP-1s to understand what to look for in a pharmacy.

Insurance Coverage: What to Expect

Insurance coverage for GLP-1s remains inconsistent. Here's where things stand in 2026:

• Medicare Part D now covers Zepbound for obesity (BMI ≥30 or ≥27 with comorbidity) following 2025 CMS rule changes. Wegovy coverage under Medicare is also expanding.
• Medicaid coverage varies by state — some states cover GLP-1s for obesity, many don't.
• Commercial insurance — roughly 50% of employer plans now cover at least one GLP-1 for obesity. Most require prior authorization with documentation of BMI and failed conventional treatments.
• No insurance or high out-of-pocket? Compounded versions are the most cost-effective route, and Truventa's providers can prescribe them.

Who Should Choose Wegovy (Semaglutide)?

• You have a history of GI sensitivity and want the slightly milder GLP-1-only mechanism
• Your insurance covers Wegovy but not Zepbound
• You've already started semaglutide and are seeing good results — there's no reason to switch
• You have cardiovascular disease: the SELECT trial showed semaglutide reduced major cardiovascular events by 20% in people with existing CVD and obesity
• You want the longest track record — semaglutide has more long-term safety data

Who Should Choose Zepbound (Tirzepatide)?

• You want the highest average weight loss potential — SURMOUNT data is compelling
• You have type 2 diabetes or significant insulin resistance — tirzepatide's GIP action provides additional metabolic benefits
• You've tried semaglutide and hit a plateau
• Your insurance covers Zepbound, or you're paying out-of-pocket and want the best ROI on weight loss
• Your BMI is higher (40+) and you want the medication with the highest ceiling for total loss

What About Compounded Versions?

During the GLP-1 shortage period of 2023–2025, the FDA allowed compounding pharmacies to produce semaglutide and tirzepatide. As of 2026, brand-name availability has largely stabilized — but compounded versions remain legal and available through licensed 503B outsourcing facilities, which are FDA-registered and held to rigorous manufacturing standards.

Truventa Medical works exclusively with vetted 503B compounding pharmacies that perform third-party purity and potency testing. This is not the gray-market "peptide research chemical" world — it's pharmaceutical-grade medication prescribed by licensed providers and dispensed by licensed pharmacies.

If cost is a barrier, compounded semaglutide or tirzepatide at $299–$399/month is a legitimate, safe, and effective option. See Truventa's weight loss programs to get started.

The Bottom Line

If you want the medication with the highest average weight loss in clinical trials, Zepbound (tirzepatide) wins on the numbers. If cardiovascular risk reduction is your primary concern or you're more GI-sensitive, Wegovy (semaglutide) is an excellent choice with a longer track record. Both are dramatically more effective than any lifestyle intervention alone.

The best GLP-1 is the one you actually tolerate and stay on. A licensed provider can review your health history, goals, and current medications to recommend the right one — and get you started within days, not months.